This analysis demonstrates that out-of-pocket costs for non-insulin diabetes medications can be extremely high for patients with employer-sponsored insurance, with those taking multiple drug classes facing potential annual costs approaching $3,000. This evidence concerns the gene INS and diabetes mellitus.